| Revision as of 10:15, 21 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,045 edits Saving copy of the {{drugbox}} taken from revid 461583394 of page Bemiparin_sodium for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 16:01, 7 February 2024 edit Citation bot (talk | contribs)Bots5,450,590 edits Removed parameters. | Use this bot. Report bugs. | Suggested by AManWithNoPlan | #UCB_CommandLineTag: Manual revert |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| Watchedfields = changed |
|
| Watchedfields = changed |
|
| verifiedrevid = 447909945 |
|
| verifiedrevid = 461744899 |
|
| IUPAC_name = |
|
| IUPAC_name = |
|
| image = |
|
| image = File:Heparin General Structure V.1.svg |
|
⚫ |
<!-- Clinical data --> |
|
|
|
|
|
| tradename = Badyket, Ivor, Hibor, Zibor, others |
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
|
| Drugs.com = {{drugs.com|international|bemiparin-sodium}} |
|
| Drugs.com = {{drugs.com|international|bemiparin-sodium}} |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = ] (except for ]) |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
|
⚫ |
| bioavailability = 96% (estimated) |
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
|
| protein_bound = |
| ⚫ |
| bioavailability = |
|
|
| protein_bound = |
|
| metabolism = |
|
⚫ |
| elimination_half-life = 5–6 hours |
|
| metabolism = |
|
|
⚫ |
| excretion = |
| ⚫ |
| elimination_half-life = |
|
|
⚫ |
<!-- Identifiers --> |
| ⚫ |
| excretion = |
|
|
⚫ |
| CAS_number_Ref = {{cascite|changed|??}} |
|
|
|
|
⚫ |
| CAS_number = 91449-79-5 |
| ⚫ |
<!--Identifiers--> |
|
| ⚫ |
| CAS_number_Ref = {{cascite|correct|??}} |
|
| ⚫ |
| CAS_number = <!-- blanked - oldvalue: 91449-79-5 --> |
|
|
| ATC_prefix = B01 |
|
| ATC_prefix = B01 |
|
| ATC_suffix = AB12 |
|
| ATC_suffix = AB12 |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
|
| DrugBank = |
|
| DrugBank = DB09258 |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
⚫ |
| chemical_formula = |
| ⚫ |
<!--Chemical data--> |
|
|
|
| molecular_weight = 3600 |
| ⚫ |
| chemical_formula = |
|
|
| molecular_weight = 3600 ] (average) |
|
| molecular_weight_comment = g/mol (average) |
|
}} |
|
}} |
|
|
'''Bemiparin''' (trade names '''Ivor''' and '''Zibor''', among others) is an ] and belongs to the group of ]s (LMWH).<ref>{{cite journal | vauthors = Chapman TM, Goa KL | title = Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis | journal = Drugs | volume = 63 | issue = 21 | pages = 2357–77 | year = 2003 | pmid = 14524738 | doi = 10.2165/00003495-200363210-00009 | s2cid = 195692039 }}</ref> |
|
|
|
|
|
==Medical uses== |
|
|
Bemiparin is used for the prevention of ] after surgery, and to prevent blood clotting in the ] circuit in ].<ref name="AC">{{cite book|title=Austria-Codex|at=Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2018|language=de}}</ref> |
|
|
|
|
|
==Contraindications== |
|
|
The medication is contraindicated in patients with a history of ] with or without ]; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or ] impairment; and acute or ].<ref name="AC" /> |
|
|
|
|
|
== Interactions == |
|
|
|
|
|
No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants, ] and other ]s, ]s, and ]s.<ref name="AC" /> |
|
|
|
|
|
==Chemistry== |
|
|
Like ], bemiparin is classified as an ultra-LMWH because of its low ] of 3600 g/mol on average.<ref>{{cite journal | vauthors = Planès A | title = Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism | journal = Expert Opinion on Pharmacotherapy | volume = 4 | issue = 9 | pages = 1551–61 | date = September 2003 | pmid = 12943485 | doi = 10.1517/14656566.4.9.1551 | s2cid = 13566575 }}</ref> (] has 4500 g/mol.) These heparins have lower anti-] activity than classical LMWHs and act mainly on ], reducing the risk of bleeding.<ref>{{cite journal | vauthors = Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C | title = A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin | journal = Thrombosis Research | volume = 128 | issue = 4 | pages = 361–7 | date = October 2011 | pmid = 21458847 | doi = 10.1016/j.thromres.2011.03.001 }}</ref> |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
== External links == |
|
|
* {{MeshName|bemiparin}} |
|
|
|
|
|
{{Antithrombotics}} |
|
|
|
|
|
] |
|
|
] |